BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. It consists of 15 amino acids and has been the subject of extensive preclinical research, primarily in rodent models, demonstrating a remarkable range of regenerative and protective effects.
Mechanism of Action
BPC-157 appears to work through several overlapping mechanisms. It upregulates growth hormone receptors in tendon fibroblasts, accelerating the repair of connective tissue. It modulates nitric oxide synthesis, improving blood flow to injured areas. It interacts with the dopaminergic and serotonergic systems, which may explain some of its reported effects on mood and gut motility. And it appears to activate the FAK-paxillin pathway, which plays a central role in cell migration and wound healing.
The Evidence Base
The preclinical literature on BPC-157 is extensive and generally consistent. Studies have demonstrated accelerated healing of tendons, ligaments, muscles, bones, and gut tissue. Anti-inflammatory effects have been observed across multiple models. Gastroprotective effects — including protection against NSAID-induced damage — have been particularly well-replicated.
What's notably absent is robust human clinical trial data. BPC-157 has not completed Phase II or Phase III trials in humans for any indication. The human evidence is largely anecdotal, drawn from the biohacking and sports medicine communities.
Common Applications
Based on the preclinical evidence and anecdotal reports, BPC-157 is most commonly used for: accelerating recovery from tendon and ligament injuries, addressing chronic joint pain, supporting gut healing in conditions like IBS or leaky gut, and as a general recovery accelerator for athletes.
Administration
BPC-157 is typically administered via subcutaneous injection near the site of injury, though some users report benefits from oral administration for gut-related applications. Injectable protocols generally range from 200–500mcg per day, often in cycles of 4–6 weeks.
Safety Profile
In animal studies, BPC-157 has demonstrated a remarkably clean safety profile with no observed toxicity even at high doses. No serious adverse events have been reported in the anecdotal human literature. That said, the absence of formal human safety trials means long-term effects are unknown.
PeptidePilot Assessment
BPC-157 is one of the most consistently recommended peptides in our algorithm for users with joint pain, injury recovery needs, or gut health concerns. The preclinical evidence is among the strongest in the research peptide space, and the anecdotal human evidence is broadly consistent with the animal data.